MTOR and ovarian carcinoma: Finally, recent studies by Muranen et al. described matrix-dependent resistance to dual-specificity PI3K/mTOR inhibitor BEZ235 and other PI3K or mTOR inhibitors, such as Rapamycin, LY294002, GDC0941, and PIK-90, in ovarian cancer cell lines (29).